Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction.

ABSTRACT:

Introduction

High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesalazine may be required during periods of remission in order to prevent relapse.

Aim

The aim of the study was to investigate clinical outcomes of three mesalazine maintenance doses adapted for post induction response.

Methods

In this post hoc analysis, 675 UC patients entered an open-label extension study for a total of 38 weeks (including 8-12 week induction period with 3.2 g/day mesalazine). After the induction period, they were separated into three groups: remitters (in clinical and endoscopic remission), responders (decre

SUBMITTER: D'Haens G 

PROVIDER: S-EPMC10601940 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature